InvestorsHub Logo
icon url

doogdilinger

02/12/18 10:08 AM

#32663 RE: Biotech junkie #32661

Very interesting statement there on Purdue's new painkiller direction agreed Junkie!

So the question now becomes are they just gonna walk away from the billions in OxyContin revs they've generated/continue generating...or are they really just providing window dressing moves/maneuvers to appease all the scrutiny they're drawing on how they've been marketing OxyContin over the many years.

If they do come up with non-opioid based pain medicines for patients...what will become of their OxyContin sales right?

That is gonna be the real underlying question now that they've cut their OxyContin sales force in half and begun abandoning their tried tested and true direct to physicians OxyContin promoting endeavors.

So far cutting their OxyContin sales force in half and no longer directly promoting OxyContin to Doctor's is clearly a strong signal that they're being sincere about reducing OxyContin sales. We just don't know how serious and how rapid their ongoing efforts to reducing OxyContin sales will be...but time will certainly tell as these next couple of years unfold.
icon url

wimuskyfisherman

02/12/18 10:20 AM

#32666 RE: Biotech junkie #32661

Junkie- In my opinion, this latest development by Perdue is due to all the litigation. The info just said they will not promote opiods to Drs. My guess is they will continue to sell as much opiod product as they can but they will no longer be wining and dining Drs out in the open. this is nothing more than a legal ploy in the face of all the litigation.